WuXi PharmaTech Attempts To Tame The Tiger Of Labor Inflation As It Feels The Pinch In 2012: China Earnings Roundup (Part 2)
This article was originally published in PharmAsia News
WuXi invests heavily to offer differentiated services with premium prices to counter growing labor costs in China; moves more facilities inland for cheaper labor.
You may also be interested in...
China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas
SHANGHAI - Leading Chinese contract research organization WuXi PharmaTech Co., Ltd. recorded a strong quarter with revenue up 16% over the same period last year to $93.6 million, and the company is readying itself for big increases in its manufacturing business thanks to large-scale contracts generated from discovery deals
HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market